INSTITUT CURIE

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Established: 1909-01-01

Employees: 1K

Market Cap: -

Website: http://www.curie.fr

Clinical Trials

Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)

Not Applicable

Completed

Conditions: Women With BRCA1 Germline Deleterious Mutation

Interventions: Procedure: Blood sampling

First Posted Date: 2015-11-18

Last Posted Date: 2024-01-31

Lead Sponsor: Institut Curie

Target Recruit Count: 200

Registration Number: NCT02608346

Locations: 🇫🇷
Hôpital René Huguenin - Institut Curie, Saint-cloud, France
🇫🇷
Institut Gustave ROUSSY, Villejuif, France
🇫🇷
Institut Curie, Paris, France

and more 1 locations

Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology

Not Applicable

Terminated

Conditions: Cervical Cancer

Interventions: Procedure: Tumor biopsy
Procedure: Blood sampling

First Posted Date: 2015-09-18

Last Posted Date: 2019-03-20

Lead Sponsor: Institut Curie

Target Recruit Count: 26

Registration Number: NCT02554565

Locations: 🇫🇷
Centre François Baclesse, Caen, France
🇫🇷
CHU Besançon, Besancon, France
🇫🇷
Centre Jean Perrin, Clermont Ferrand, France

and more 1 locations

Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor - NGSKids

Not Applicable

Completed

Conditions: Metastatic and/or High Risk Solid Tumor of Children

Interventions: Biological: Tumoral specific genetic alterations

First Posted Date: 2015-09-10

Last Posted Date: 2024-01-31

Lead Sponsor: Institut Curie

Target Recruit Count: 30

Registration Number: NCT02546453

Locations: 🇫🇷
Institut Curie, Paris, France

Characterisation of Biofilm of the Chronic Wounds

Not Applicable

Completed

Conditions: Chronic Wounds

Interventions: Biological: 1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing

First Posted Date: 2015-08-10

Last Posted Date: 2015-08-10

Lead Sponsor: Institut Curie

Target Recruit Count: 130

Registration Number: NCT02519166

Locations: 🇫🇷
Hopital Rothschild, Paris, France
🇫🇷
Institut Curie, Paris, France
🇫🇷
Chu Montpellier, Montpellier, France

PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 2

Terminated

Conditions: Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome
Acute Myeloid Leukemia, in Relapse
de Novo Acute Myeloid Leukemia at Diagnostic

Interventions: Drug: PF-05212384

First Posted Date: 2015-05-08

Last Posted Date: 2019-02-06

Lead Sponsor: Institut Curie

Target Recruit Count: 10

Registration Number: NCT02438761

Locations: 🇫🇷
Hôpital Saint-Louis, Paris, Ile De France, France
🇫🇷
Institut Curie - Hôpital René Huguenin, Saint-Cloud, Ile De France, France
🇫🇷
CHU de Toulouse, Toulouse, Midi-Pyrénées, France

and more 2 locations

Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)

Not Applicable

Completed

Conditions: Cervical Cancer

Interventions: Procedure: Tumor biopsies
Procedure: Blood sampling

First Posted Date: 2015-04-29

Last Posted Date: 2023-01-20

Lead Sponsor: Institut Curie

Target Recruit Count: 419

Registration Number: NCT02428842

Locations: 🇷🇴
Teo Health S.A. - Spitalul Sf. Constantin, Brasov, Romania
🇷🇸
Clinic for operative oncology, Institute of oncology of Vojvodina, Sremska Kamenica, Serbia
🇷🇴
Spitalul Clinic Municipal "Gavril Curteanu", Oradea, Romania

and more 21 locations

MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery

Phase 3

Completed

Conditions: Malignant Neoplasm of Breast

Interventions: Drug: Saline
Drug: Ropivacaine

First Posted Date: 2015-04-03

Last Posted Date: 2019-07-10

Lead Sponsor: Institut Curie

Target Recruit Count: 380

Registration Number: NCT02408393

Locations: 🇫🇷
INSTITUT CURIE - Site Paris, Paris, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Institut de Cancérologie de Lorraine, Vandoeuvre-les-nancy, France

and more 3 locations

Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer

Phase 1

Terminated

Conditions: Pleural Effusion, Malignant
Breast Cancer

Interventions: Drug: Bevacizumab

First Posted Date: 2014-09-26

Last Posted Date: 2017-11-06

Lead Sponsor: Institut Curie

Target Recruit Count: 1

Registration Number: NCT02250118

Locations: 🇫🇷
Institut Curie - Hôpital René Huguenin, Saint-Cloud, France

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial

Phase 2

Completed

Conditions: First Relapse
Multiple Myeloma

Interventions: Drug: PCD
Procedure: Autologous transplantation (ASCT)

First Posted Date: 2014-09-18

Last Posted Date: 2023-07-05

Lead Sponsor: Institut Curie

Target Recruit Count: 100

Registration Number: NCT02244125

Locations: 🇫🇷
CHRU Hopital Sud, Amiens, France
🇫🇷
Centre Hospitalier de la côte Basque, Bayonne, France
🇫🇷
Hôpital Avicenne, Bobigny, France

and more 27 locations

Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology

Not Applicable

Conditions: Solid Tumor.

First Posted Date: 2014-08-20

Last Posted Date: 2016-07-07

Lead Sponsor: Institut Curie

Target Recruit Count: 360

Registration Number: NCT02220556

Locations: 🇫🇷
Institut Mutualiste Montsouris, Paris, France
🇫🇷
Institut Curie, Saint-Cloud, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy